Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

NASDAQ: ONTX was downgraded by Zacks Investment Research  from a “buy” ranking to a “hold” ranking in a research note issued to financiers on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on uncovering as well as establishing small particle medication prospects to deal with cancer. The Firm‘s items under various phases of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several various other equities research analysts also just recently talked about the business. Noble Financial reissued a “purchase” rating and released a $11.00 rate goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving typical rate of $2.90 as well as a two-hundred day moving typical rate of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) earnings per share for the quarter, topping experts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an adverse net margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, contrasted to the agreement quote of $0.06 million. During the exact same quarter in the previous year, the firm uploaded ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will publish -1.18 EPS for the current year.

A number of hedge funds have recently dealt shares of ONTX. GSA Resources Allies LLP purchased a new setting in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Funding Management LP got a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC acquired a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional capitalists own 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition and development of oncology therapeutics. It concentrates on discovering and also establishing small molecule drug candidates to treat cancer cells. The company was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more information regarding research offerings from Zacks Investment Research, browse through Zacks.com.

This immediate news alert was generated by narrative scientific research innovation as well as financial data from Market in order to offer readers with the fastest and most accurate coverage. This tale was assessed by Market’s content team before publication. 



Prior to you consider Onconova Therapeutics, you’ll wish to hear this.

Market monitors Wall Street’s top-rated and also ideal executing research experts as well as the stocks they recommend to their customers daily. Market has actually determined the 5 stocks that top analysts are quietly whispering to their customers to buy currently before the more comprehensive market catches on … and also Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” rating amongst analysts, top-rated experts believe these five stocks are much better gets.